SLRX News & Events

Salarius Pharmaceuticals will change its corporate name to Decoy Therapeutics and its common shares will trade on the Nasdaq Capital Market under the ticker symbol DCOY effective as of commencement of trading on January 8. These changes reflect the Company's focus on developing novel peptide-conjugate therapeutics through its proprietary platform that reduces the complexity of drug development and manufacturing. "Changing our corporate name is another step in our transformation to developing the next generation of peptide-conjugate therapeutics, with an initial emphasis on high-priority viral and oncology targets," said Rick Pierce, CEO. "With an AI-enabled discovery engine, a lead antiviral program of interest to global health stakeholders and a tightly focused 2026 plan, we are positioned to advance our first program into the clinic, expand our pipeline and create long-term value for patients and shareholders." These changes do not affect the total number of shares outstanding, shareholders' rights, the CUSIP number or the transfer agent, nor do they impact the Company's operations or leadership, which includes Decoy's senior management team and Salarius' finance team. The Company's priorities for 2026 include: Advancing lead antiviral programs toward regulatory readiness; Expanding discovery and preclinical validation across multiple platforms; Leveraging AI-enabled computational infrastructure to accelerate candidate selection; Pursuing strategic collaborations with big pharma, technology leaders and academic institutions; Strengthening the Company's capital structure and expanding investor visibility.

Salarius Pharmaceuticals announced that in connection with its recent combination with Decoy Therapeutics, the Company intends to change its corporate name to Decoy Therapeutics Inc. and its NASDAQ ticker symbol to DCOY. The planned name and ticker change mark a pivotal step in the Company's transformation into a platform-driven biotechnology company focused on novel peptide-conjugate therapeutics with applications across viral diseases and oncology. The Company expects the name and ticker symbol change to become effective in early January 2026. The Company will continue to trade under the existing symbol SLRX until the effective date. The Company's transfer agent will remain unchanged. Stockholder approval was not required to take any specific action with respect to the corporate name change or new ticker symbol. The corporate name change and new ticker symbol will not impact the Company's operations. As previously announced Decoy's senior management team joined by Salarius's finance team will lead the new Company's operations. Looking ahead, the Company plans to prioritize: Advancing lead antiviral programs toward regulatory readiness; Expanding discovery and preclinical validation across multiple platforms; Leveraging AI-enabled computational infrastructure to accelerate candidate selection; Pursuing strategic collaborations with big pharma, technology leaders, and academic institutions; Strengthening the Company's capital structure and investor visibility. The Company believes this execution-focused approach positions Decoy Therapeutics to generate multiple shots on goal while retaining upside through partnerships and non-dilutive funding sources

Decoy Therapeutics and Texas Biomedical Research Institute announce a collaboration to conduct in vitro testing of Decoy's peptide conjugate fusion inhibitors across several influenza strains including H5N1 avian flu. The addition of pan-influenza inhibitors to Salarius' previously designed pan-coronavirus and pan-paramyxovirus inhibitors supports the Company's goal of using its IMP3ACT platform to create a single antiviral inhibitor that is broadly effective against the three viral families that are responsible for the majority of serious seasonal respiratory viral infections. Additionally, Salarius intends to explore the use of these peptides for agricultural health applications such as the treatment of egg-laying poultry flocks.

Salarius Pharmaceuticals cites an error on the S&P CapIQ platform and reiterates that its common stock continues to trade uninterrupted on the Nasdaq Stock Market under the stock ticker "SLRX." The company stated: "S&P CapIQ inaccurately characterized the Salarius Pharmaceuticals and Decoy Therapeutics merger and inaccurately stated that the Company had been delisted from the Nasdaq Capital Market. The Company is working to have this inaccurate information corrected. Similar inaccuracies that appeared on Yahoo Finance were corrected earlier this week. On November 13, 2025, Salarius completed an underwritten public offering raising gross proceeds of $8 million and consummated the previously announced merger with Decoy Therapeutics. As of the date of this release, the combined company had pro forma cash of approximately $14 million and approximately 5.9 million shares of common stock outstanding. The company is focused on advancing Decoy's pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. During the next 12 months, Decoy expects to advance its lead asset, a pan-coronavirus antiviral, to the filing of an Investigational New Drug application with the U.S. Food and Drug Administration, and to make progress on other programs including a novel broad-acting antiviral to treat flu, COVID-19 and respiratory syncytial virus, and a peptide drug conjugate targeting GI cancers."